- Home
- OIA vs LCTX Comparison
OIA vs LCTX Comparison
Compare OIA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIA | LCTX |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.8M | 301.7M |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OIA | LCTX |
|---|---|---|
| Price | $5.97 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 127.3K | ★ 935.1K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $5.60 | $1.00 |
| 52 Week High | $6.40 | $2.09 |
Technical Indicators
Market Signals| Indicator | OIA | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 44.77 |
| Support Level | $5.97 | $1.00 |
| Resistance Level | $6.25 | $1.18 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 10.71 | 32.14 |
Price Performance
Historical ComparisonAbout OIA Invesco Municipal Income Opportunities Trust
Invesco Municipal Income Opportunities Trust is a closed-end management investment company. The Trust's investment objective is to provide a high level of current income which is exempt from federal income tax.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.